Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

T cell defined tumor antigens

B J Van den Eynde1, P van der Bruggen

  • 1Ludwig Institute for Cancer Research, Brussels, Belgium. vandeneynde@licr.ucl.ac.be

Current Opinion in Immunology
|November 22, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes.

Scientific reports·2016
Same author

Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines.

Journal of cellular and molecular medicine·2010
Same author

[Is it possible to correct the anergy of T lymphocytes that infiltrate tumors?].

Bulletin et memoires de l'Academie royale de medecine de Belgique·2010
Same author

Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines.

Gene therapy·2005
Same author

A peptide derived from melanocytic protein gp100 and presented by HLA-B35 is recognized by autologous cytolytic T lymphocytes on melanoma cells.

Tissue antigens·2005
Same author

A novel approach to identify antigens recognized by CD4 T cells using complement-opsonized bacteria expressing a cDNA library.

Leukemia·2004
Same journal

The food additive microbial transglutaminase is a potential new environmental inducer of autoimmune diseases.

Current opinion in immunology·2026
Same journal

Mapping the synovial immune ecosystem in rheumatoid arthritis: cellular cartography and pathotype-guided immune restoration.

Current opinion in immunology·2026
Same journal

Noncanonical ion channel signaling in neurovascular barrier regulation and immune cell trafficking.

Current opinion in immunology·2026
Same journal

A blind spot of human T cell immunology: epitope specificity in secondary lymphoid organs.

Current opinion in immunology·2026
Same journal

Germinal center responses at barrier organ sites.

Current opinion in immunology·2026
Same journal

Ocular sarcoidosis: from clinical signs to targeted interventions.

Current opinion in immunology·2026
See all related articles

Researchers are identifying tumor antigens resulting from specific mutations. Early clinical trials are now exploring the potential of immunizing against these antigens for effective antitumor therapy.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • T cell-defined tumor antigens are increasingly identified across diverse cancer types in humans and mice.
  • A growing subset of these antigens originates from tumor-specific mutations, some potentially driving cancer development (oncogenesis).

Purpose of the Study:

  • To assess the clinical utility of immunizing against tumor-specific antigens for cancer treatment.
  • To present emerging data from initial clinical trials evaluating this therapeutic approach.

Main Methods:

  • Characterization of T cell-defined antigens in various tumor models.
  • Analysis of tumor-specific mutations linked to antigen presentation.
  • Conducting and analyzing pilot clinical studies for antitumor immunotherapy.

Related Experiment Videos

Main Results:

  • A wide range of tumor antigens has been identified.
  • Tumor-specific mutations are a significant source of these antigens.
  • Initial clinical pilot studies are yielding preliminary results on therapeutic efficacy.

Conclusions:

  • T cell-defined antigens, particularly those arising from tumor mutations, represent promising targets for cancer immunotherapy.
  • Further clinical investigation is warranted to validate the therapeutic potential of antigen-specific immunization in cancer patients.